GILD - Can Gilead Recover After Latest Earnings Downfall?
Gilead Sciences (GILD) has a very tough road ahead after its latest earnings report. The earnings for the fourth quarter were mixed, but the company needs to take drastic action to redeem itself. The revenue may have come in over expectations, but it won't be long until Gilead finds itself in a very tough situation to get out of. I believe a solid solution would be to acquire other pharmaceutical companies that could help diversify it away from all the current programs. I recommend acquisitions that will be good for long-term growth, but I believe